Your session is about to expire
← Back to Search
Belzutifan for Kidney Cancer
Study Summary
This trial is testing a new drug for people with kidney cancer that has spread. They want to see if it is safe and how it affects the body.
Eligibility Criteria
Inclusion Criteria
You may be eligible if you check “Yes” for the criteria belowTimeline
Treatment Details
Study Objectives
Outcome measures can provide a clearer picture of what you can expect from a treatment.Trial Design
Find a Location
Who is running the clinical trial?
Media Library
- My kidney cancer cannot be surgically removed and has spread.I have not taken any CSFs within the last 28 days.I have been treated with belzutifan before.I have a history of GI issues or liver problems.My organs are functioning well.I had radiotherapy less than 2 weeks ago.My kidney cancer has worsened after at least one treatment.I have serious heart issues or had a recent heart procedure.I am a male willing to use contraception or abstain from sex during and 7 days after the study.My liver is not working well.I have another cancer besides the one being studied, but it hasn't needed treatment in the last 3 years.I need extra oxygen sometimes or all the time.I have not had major surgery in the last 3 weeks.You have HIV, hepatitis B, or hepatitis C infections.I am currently being treated for an active infection.I have had or currently have cancer spread to my brain or its coverings.I am not pregnant, breastfeeding, and if able to have children, I am using contraception or abstaining from sex.I haven't had cancer treatment with antibodies in the last 4 weeks.I have recovered from side effects of past treatments, except for mild neuropathy.
- Group 1: Belzutifan 160 mg BID
- Group 2: Belzutifan 160 mg TID
- Group 3: Belzutifan 200 mg TID
- Group 4: Belzutifan 120 mg QD
- No Placebo-Only Group - All patients enrolled in this study will receive some form of active treatment.
- Screening: It may take up to 3 Weeks to process to see if you qualify in this trial.
- Treatment: The duration you will receive the treatment varies.
- Follow Ups: You may be asked to continue sharing information regarding the trial for 6 Months after you stop receiving the treatment.
Frequently Asked Questions
How many participants has the clinical trial enrolled thus far?
"Yes indeed, the information on clinicaltrials.gov specifies that recruitment for this experiment is in progress. It was published on June 14th 2021 and edited lastly on June 23rd 2022 with a requirement of 52 participants from 4 distinct medical sites."
Has the FDA granted clearance for Belzutifan?
"Due to its Phase 1 designation, Belzutifan has only limited clinical data on both safety and efficacy prompting us at Power to rate it a score of 1."
What is the number of medical facilities that are currently administering this trial?
"This research is recruiting patients at the University of Michigan in Ann Arbor, Vanderbilt University Medical Center-Vanderbilt-Ingram Cancer Centre in Nashville, and the MD Anderson Cancer Centre's Genitourinary Oncology Department. There are several other sites as well."
Are there any opportunities to join this research project currently available?
"Affirmative. The information on clinicaltrials.gov confirms that this study is presently recruiting; the original post was dated June 14th 2021 and it underwent an update as recently as June 23rd 2022. This experiment requires 52 volunteers from 4 diverse sites to participate."
What condition is Belzutifan commonly used to alleviate?
"Belzutifan has been medically proven to help tackle malignant neoplasms, anemia, sickle cell disease and the inherited disorder von Hippel Lindau."
Could you detail any other investigations conducted on Belzutifan?
"Currently, the investigation of Belzutifan is being conducted in 16 different studies. Out of these experiments, three are actively recruiting subjects and have reached Phase 3. Although most research sites are located in Cardiff, Wales there exist 859 medical facilities running trials for this treatment."
Is this a pioneering or unprecedented research endeavor?
"Research into Belzutifan began in 2016, and the initial study was sponsored by Peloton Therapeutics, Inc. In this original trial 120 patients were involved which allowed for a Phase 1 drug approval to be issued. As of now 16 trials are ongoing within 44 countries across 372 cities worldwide."
Share this study with friends
Copy Link
Messenger